Azenosertib
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Serous Carcinoma
Conditions
Uterine Serous Carcinoma
Trial Timeline
Jul 28, 2021 → Oct 22, 2025
NCT ID
NCT04814108About Azenosertib
Azenosertib is a phase 2 stage product being developed by Zentalis Pharmaceuticals for Uterine Serous Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04814108. Target conditions include Uterine Serous Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05128825 | Phase 2 | Recruiting |
| NCT04814108 | Phase 2 | Completed |
| NCT04158336 | Phase 1 | Completed |
Competing Products
20 competing products in Uterine Serous Carcinoma